Histopathological Features of Late Liver Allograft Dysfunction.
10.4285/jkstn.2013.27.4.153
- Author:
Eunsil YU
1
Author Information
1. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. d890075@gmail.com
- Publication Type:Review
- Keywords:
Liver transplantation;
Graft rejection;
Hepatitis;
Recurrence
- MeSH:
Antibodies;
Biopsy;
Chungcheongnam-do;
Consensus;
Diagnosis;
Diagnosis, Differential;
DNA;
Graft Rejection;
Hepatitis;
Hepatitis B;
Hepatitis, Autoimmune;
Humans;
Liver Diseases;
Liver Transplantation;
Liver*;
Lymphoproliferative Disorders;
Recurrence;
Serologic Tests;
Transplantation, Homologous*;
Viruses
- From:The Journal of the Korean Society for Transplantation
2013;27(4):153-159
- CountryRepublic of Korea
- Language:English
-
Abstract:
Interpretation of late allograft biopsies can be challenging because of overlapping clinicopathological features, regional difference of underlying liver diseases for liver transplantation, and continuous changing of preoperative treatment modalities of native liver diseases. In this review article, the potential causes and histopathological features of late allograft dysfunction are discussed. The causes include recurrence of native liver disease, late-onset acute rejection, chronic rejection, and posttransplant malignancy or hepatitis of unknown etiology. Differential diagnosis between recurrent or late-onset acute rejection and early-stage chronic rejection, either reversible or finally leading to late-stage chronic rejection, is practically difficult; however, clinically, it affects patient treatment. Diagnosis of recurrent hepatitis B virus/hepatitis C virus hepatitis should be made with consideration of both serological evaluation for deoxyribonucleic acid, ribo nucleic acid, or antibodies and histopathological features. Although differentiation of recurrent or de novo autoimmune hepatitis from acute rejection is difficult, patients with autoimmune hepatitis undergo similar treatment. In pediatric patients, evaluation of Epstein-Barr virus-associated changes, which vary from nonspecific hepatitis to post- transplant lymphoproliferative disorder with or without acute rejection, is practically important from the point of treatment. From our 16-year experience in Asan Medical Center, it has become clear that the histopathological diagnosis of late allograft biopsies must be made on the basis of consensus criteria for the common and problematic causes of late complications of liver transplantations proposed by the Banff Working Group, by integration of clinical features and results of key serological tests, and even by consideration of responses to previous treatment.